Radiopharmaceutical Market Size, Share, Trends, Growth and Forecast 2028

Radiopharmaceutical Market

Radiopharmaceutical Market - By Radioisotope Type (Technetium-99, Fluorine-18, Iodine-131, and Leutetium-177), By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, and Nephrology), By Source (Cyclotrons and Nuclear Reactors), and By End-User (Hospitals and Diagnostic Labs): Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2022 – 2028

Category: Pharmaceutical Report Format : PDF Pages: 190 Report Code: ZMR-86 Published Date: Apr-2022 Status : Published

Radiopharmaceutical Market accrued earnings worth 5.8(USD Billion) in 2021 and is predicted to gain revenue of about 11.9(USD Billion) by 2028

Globa Radiopharmaceutical Market Overview:

The global Radiopharmaceutical Market accrued earnings worth approximately 5.8(USD Billion) in 2021 and is predicted to gain revenue of about 11.9(USD Billion) by 2028, is set to record a CAGR of nearly 8.2% over the period from 2022 to 2028. The study provides assessment and analysis of the Radiopharmaceutical Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).

Global Radiopharmaceutical Market SizeRequest Free Sample

Radiopharmaceutical Market: Outlook

Radiopharmaceuticals are a class of radioactive substances that can be utilized for therapeutic purpose or diagnostic purpose. Moreover, radiopharmaceuticals find large-scale applications in breast cancer and neuroendocrine tumors. In addition to this, the product also finds myriad utility in nuclear medicine. However, administration of radiopharmaceuticals is systemic and they are projected to be restricted to particular tissues owing to its bio-molecular features. Additionally, radiopharmaceuticals actively emit radiation and this makes their storage difficult in comparison to non-radioactive pharmaceuticals. This has restricted use of radiopharmaceuticals.

Global Radiopharmaceutical MarketRequest Free Sample

Radiopharmaceutical Market: Growth Drivers

Rise in occurrence of ailments such as heart disorders, neurological ailments, and cancer will boost radiopharmaceutical market trends. Prominent surge in use of nuclear medicine in oncology has prompted demand for radiopharmaceuticals in recent years. In addition to this, launching of new technologies in nuclear imaging systems including PET and SPECT will prop up expansion of radiopharmaceutical industry. Nevertheless, huge costs of producing radiopharmaceuticals against ROI and strict laws governing radioactive emissions will put brakes on growth of radiopharmaceutical industry.

Furthermore, surge in research & development activities is projected to steer growth of radiopharmaceutical industry. Moreover, surge in patient awareness, need of precise diagnosis, and rise in use of molecular imaging techniques will embellish growth of radiopharmaceutical market. Use of monoclonal antibodies & radiolabeled peptides for identifying and treating malignant tumors will steer expansion of radiopharmaceuticals industry. Need for treating various kinds of diseases and massive use of targeted treatments such as radiopharmaceutical therapy will proliferate expansion of radiopharmaceutical market.

Global Radiopharmaceutical Market Report Scope:

Report Attributes Report Details
Report Name Radiopharmaceutical Market
Market Size in 2021 USD 5.8 Billion
Market Forecast in 2028 USD 11.9 Billion
Compound Annual Growth Rate CAGR of 8.2%
Number of Pages 190
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered Jubilant Pharmova, Lantheus Holdings Inc., Mallinckrodt Pharmaceuticals, Cardinal Health Inc., GE Healthcare, Advanced Accelerator Applications, The Bracco Group, Eczacibasi-Monrol Nuclear Products, Nordion Inc., Bayer AG, IBA Molecular Imaging Private Limited, and Siemens Healthineers AG.
Segments Covered By Radioisotope, By Application, By Source, By End-User And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latian America, Middle East and Africa (MEA)
Countries Covered North America: U.S and Canada
Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
Latin America: Brazil, Argentina, Chile
The Middle East And Africa: South Africa, GCC, Rest of MEA
Base Year 2020
Historical Year 2016 to 2019
Forecast Year 2021 - 2028
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization


To know more about this report, request a sample copy.

Radiopharmaceutical Market: Regional Landscape

North America To Make Notable Contributions Towards Regional Market Size By 2028

Expansion of radiopharmaceutical market in North America over forecasting years can be attributed to rise in occurrence of chronic disorders such as heart ailments and cancer in countries such as the U.S. In addition to this, surging aging populace and changing lifestyles    has resulted in obesity leading to huge sale of nuclear drugs. This has driven growth of regional market. Acceptance of new technologies for radioisotope production for treating chronic ailments will result in expansion of radiopharmaceuticals market in countries such as the U.S.

Breakthroughs in Radiopharmaceutical Market

  • In March 2022, GE Healthcare declared first patient dosed in its phase III clinical experiments for PET radiopharmaceutical imaging agents. It is likely to carry out clinical trial for SPECT radiopharmaceutical imaging agent in next phase. The strategic move is aimed at diagnosing adult population for Parkinson syndrome along with enhancing patient care services. Reportedly, GE Healthcare is planning to augment its radiopharmaceutical portfolio through these two pipeline radiopharmaceuticals, one for PET and another for SPECT.  
  • In March 2022, Novartis AG won approval of U.S. Food and Drug Administration for selling radiopharmaceutical for treating advanced stage of prostate cancer.
  • In April 2022, Iran has unleashed new generation of radiopharmaceutical referred as LU-177. It is developed by Iranian scientists and is used for diagnosing as well as curing various kinds of cancerous tissues. Moreover, LU-177 has ability to kill cancer tumor tissues by linking to tumor receptors. The mechanism of LU-177 is expected to prevent metastatis through disruption of circulating blood near tumors.

Radiopharmaceutical Market: Competitive Insights

Some of the major players have lucratively impacted growth of radiopharmaceutical industry and are predicted to do so even in near future. They are Jubilant Pharmova, Lantheus Holdings Inc., Mallinckrodt Pharmaceuticals, Cardinal Health Inc., GE Healthcare, Advanced Accelerator Applications, The Bracco Group, Eczacibasi-Monrol Nuclear Products, Nordion Inc., Bayer AG, IBA Molecular Imaging Private Limited, and Siemens Healthineers AG.

The global Radiopharmaceutical Market is segmented as follows:

By Radioisotope Type

  • Technetium-99
  • Fluorine-18
  • Iodine-131
  • Leutetium-177

By Application

  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  •  Nephrology

By Source

  • Cyclotrons
  • Nuclear Reactors

By End-User

  • Hospitals
  • Diagnostic Labs

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

Rise in occurrence of ailments such as heart disorders, neurological ailments, and cancer will boost radiopharmaceutical market trends.

According to Zion market research report, the global Radiopharmaceutical Market accrued earnings worth approximately 5.8(USD Billion) in 2021 and is predicted to gain revenue of about 11.9(USD Billion) by 2028, is set to record a CAGR of nearly 8.2% over the period from 2022 to 2028.

North America will contribute sizably towards the global market revenue over the projected timeline. A massive increase in Radiopharmaceutical Market size in sub-continent over 2022-2028 can be due to rise in occurrence of chronic disorders such as heart ailments and cancer in countries such as the U.S.

The key industry participants leveraging business space include Jubilant Pharmova, Lantheus Holdings Inc., Mallinckrodt Pharmaceuticals, Cardinal Health Inc., GE Healthcare, Advanced Accelerator Applications, The Bracco Group, Eczacibasi-Monrol Nuclear Products, Nordion Inc., Bayer AG, IBA Molecular Imaging Private Limited, and Siemens Healthineers AG.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed